In short
Etravirine, an antiretroviral medication, has been the subject of several clinical trials investigating its efficacy, safety, and potential applications. These studies have primarily focused on its use in treating HIV infections, but have also explored its effects on other conditions. The trials have examined various aspects of etravirine, including its dosing regimens, pharmacokinetics, and impact on patients' quality of life.
At a glance
- Primary Use
- Treatment of HIV-1 infections
- Mechanism of Action
- Non-nucleoside reverse transcriptase inhibitor (NNRTI)
- Dosing
- Typically 200mg twice daily, with some trials exploring 400mg once daily
- Efficacy
- Effective in reducing viral load and increasing CD4+ count in HIV patients
- Side Effects
- Generally well-tolerated; fewer neuropsychiatric side effects compared to efavirenz
- Special Populations
- Studied in treatment-experienced patients and children/adolescents
- Other Applications
- Investigated for potential use in Friedreich Ataxia
- Patient Preference
- Some studies suggest improved sleep quality and fewer CNS side effects compared to efavirenz
What is Etravirine?
Etravirine, also known by its brand name Intelence or research code TMC125, is an antiretroviral medication used to treat Human Immunodeficiency Virus (HIV) infections. It belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which work by blocking a specific enzyme that HIV needs to multiply.
How Etravirine Works
Etravirine works by inhibiting the action of an enzyme called reverse transcriptase, which is essential for HIV to replicate. By doing so, it helps to reduce the amount of HIV in the body, allowing the immune system to function better and decreasing the risk of HIV-related complications. Etravirine has shown high activity against wild-type HIV-1 (the most common type of HIV) and even against HIV strains that have become resistant to other non-nucleoside agents.
Conditions Treated with Etravirine
Etravirine is primarily used to treat:
- HIV-1 Infections: It is used in combination with other antiretroviral agents to treat HIV-1 infected patients who have experience with antiretroviral treatment.
- Treatment-Experienced Patients: Etravirine is particularly useful for patients who have developed resistance to other HIV medications.
Dosage and Administration
Etravirine is typically administered as follows:
- Adult Dosage: The standard dose for adults is 200 mg (two 100 mg tablets) taken twice daily after a meal.
- Pediatric Dosage: For children and adolescents (6 years to less than 18 years old), the dose is based on body weight, ranging from 100 mg to 200 mg twice daily.
- Administration: Etravirine tablets should be swallowed whole with a liquid. For patients who have difficulty swallowing, the tablets can be dispersed in a glass of water.
Side Effects and Safety
Like all medications, Etravirine can cause side effects. Common side effects include:
- Skin rash: This is usually mild to moderate and often resolves on its own.
- Gastrointestinal issues: Such as nausea, vomiting, and diarrhea.
- Headache and fatigue.
Importantly, Etravirine has shown lower rates of central nervous system (CNS) side effects compared to some other HIV medications like Efavirenz. This includes fewer instances of dizziness, abnormal dreams, and sleep disturbances.
Drug Interactions
Etravirine can interact with other medications. It's important to inform your healthcare provider about all medications you're taking. Some notable interactions include:
- Other HIV medications: Etravirine may interact with certain protease inhibitors and other antiretroviral drugs.
- Hepatitis C medications: There may be interactions with drugs like Boceprevir.
Use in Special Populations
Etravirine use in special populations:
- Pregnancy: Animal studies have shown a low risk of birth defects, but more research is needed in humans.
- Children: Etravirine is approved for use in children 2 years of age and older.
- Elderly: Limited information is available on the use of Etravirine in patients over 65 years old.
Ongoing Research and Future Applications
Research on Etravirine is ongoing, exploring its potential in various areas:
- Once-daily dosing: Studies are investigating the efficacy of Etravirine when given once daily instead of twice daily.
- Treatment of other conditions: Etravirine is being studied for potential use in treating Friedreich's Ataxia, a rare genetic disorder affecting the nervous system.
- Improved formulations: Research is being conducted on different tablet formulations to improve swallowability and patient comfort.